Sildenafil use and increased risk of incident melanoma in US men: A prospective cohort study

JAMA Internal Medicine

Volumn 174, Issue 6, 2014, Pages 964-970

  Li, Wen Qing ^a,b   Qureshi, Abrar A ^a,b   Robinson, Kathleen C ^c,d   Han, Jiali ^a,e,f,g,h  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f INDIANA UNIVERSITY   (United States)

^g INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

SILDENAFIL;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CHRONIC DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG SCREENING; ERECTILE DYSFUNCTION; FOLLOW UP; HEALTH CARE PERSONNEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MEN'S HEALTH; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; SELF CONCEPT; SKIN CANCER; SQUAMOUS CELL CARCINOMA; UNITED STATES;

AGED; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; ERECTILE DYSFUNCTION; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PROSPECTIVE STUDIES; PURINES; SKIN NEOPLASMS; SULFONES; UNITED STATES;

EID: 84902166159     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.594     Document Type: Article

References (38)

1. Gray-Schopfer V,Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature. 2007;445(7130):851-857.
2. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet. 2005;365(9460):687-701. (Pubitemid 40260892)
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
4. Goydos JS, Mann B, Kim HJ, et al. Detection of B-RAF and N-RAS mutations in human melanoma. J AmColl Surg. 2005;200(3):362-370. (Pubitemid 40298970)
5. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417 (6892):949-954. (Pubitemid 34716871)
6. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358-365.
7. Bollag G, Tsai J, Zhang J, et al. Vemurafenib: thefirst drug approved for BRAF-mutant cancer. Nat Rev Drug Discov. 2012;11(11):873-886.
8. Arozarena I, Sanchez-Laorden B, Packer L, et al. Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell. 2011;19(1): 45-57.
9. Packer LM, East P, Reis-Filho JS, Marais R.Identification of direct transcriptional targets of V600EBRAF/MEK signalling in melanoma. PigmentCell Melanoma Res. 2009;22(6):785-798.
10. Dhomen N, Reis-Filho JS, da Rocha Dias S, et al.Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell. 2009;15(4):294-303.
11. Houslay MD. Hard times for oncogenicBRAF-expressing melanoma cells. Cancer Cell. 2011; 19(1):3-4.
12. Palit V, Eardley I. An update on new oral PDE5 inhibitors for the treatment of erectile dysfunction. Nat Rev Urol. 2010;7(11):603-609.
13. Ghofrani HA, Osterloh IH, Grimminger F.Sildenafil: from angina to erectile dysfunction topulmonary hypertension and beyond. Nat Rev DrugDiscov. 2006;5(8):689-702. (Pubitemid 44151606)
14. Zhang X, Yan G, Ji J, et al. PDE5 inhibitor promotes melanin synthesis through the PKG pathway in B16 melanoma cells. J Cell Biochem. 2012;113(8):2738-2743.
15. Noonan FP, Zaidi MR,Wolnicka-Glubisz A, et al. Melanoma induction by ultraviolet A but not ultraviolet B radiation requires melanin pigment. Nat Commun. 2012;3:884.
16. Mitra D, Robinson KC, Fisher DE. Melanoma and Viagra: an unexpected connection. Pigment Cell Melanoma Res. 2011;24(1):16-18.
17. Madan V, Lear JT, Szeimies RM. Non-melanoma skin cancer. Lancet. 2010;375(9715):673-685.
18. Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Intern Med. 2003;139(3):161-168.
19. Gao X, Schwarzschild MA, O?Reilly EJ,Wang H, Ascherio A. Restless legs syndrome and erectile dysfunction. Sleep. 2010;33(1):75-79.
20. Cho E, Rosner BA, Feskanich D, Colditz GA. Risk factors and individual probabilities of melanoma for whites. J Clin Oncol. 2005;23(12):2669-2675. (Pubitemid 46179456)
21. Han J, Colditz GA, Hunter DJ. Risk factors for skin cancers: a nested case-control study within the Nurses? Health Study. Int J Epidemiol. 2006;35(6): 1514-1521. (Pubitemid 46178928)
22. Walls AC, Han J, Li T, Qureshi AA. Host risk factors, ultraviolet index of residence, and incident malignant melanoma in situ among US women and men. Am J Epidemiol. 2013;177(9):997-1005. doi:10 .1093/aje/kws335.
23. Sergentanis TN, Antoniadis AG, Gogas HJ, et al. Obesity and risk of malignant melanoma: ameta-analysis of cohort and case-control studies. Eur J Cancer. 2013;49(3):642-657.
24. Song F, Qureshi AA, Gao X, Li T, Han J. Smoking and risk of skin cancer: a prospective analysis and a meta-analysis. Int J Epidemiol. 2012;41(6):1694-1705.
25. Colditz GA, Martin P, Stampfer MJ, et al. Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. Am J Epidemiol. 1986;123 (5):894-900. (Pubitemid 16049247)
26. Hunter DJ, Colditz GA, Stampfer MJ, Rosner B,WillettWC, Speizer FE. Diet and risk of basal cellcarcinoma of the skin in a prospective cohort ofwomen. Ann Epidemiol. 1992;2(3):231-239.
27. Sun GW, Shook TL, Kay GL. Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. J Clin Epidemiol. 1996;49(8): 907-916. (Pubitemid 26283404)
28. Azzouni F, Abu samra K. Are phosphodiesterase type 5 inhibitors associatedwith vision-threatening adverse events? a critical analysis and review of the literature. J Sex Med. 2011;8(10):2894-2903.
29. Adamo CM, Dai DF, Percival JM, et al. Sildenafil reverses cardiac dysfunction in the mdx mousemodel of Duchenne muscular dystrophy. Proc Natl Acad Sci U S A. 2010;107(44):19079-19083.
30. Das A, Durrant D, Mitchell C, et al. Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. Proc Natl Acad Sci U S A. 2010;107(42): 18202-18207.
31. Francis SH, Busch JL, Corbin JD, Sibley D. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev. 2010;62(3):525-563.
32. Khan AS, Sheikh Z, Khan S, Dwivedi R, Benjamin E. Viagra deafness-sensorineural hearing loss and phosphodiesterase-5 inhibitors. Laryngoscope. 2011;121(5):1049-1054.
33. Guo D, Tan YC,Wang D, et al. A Rac-cGMP signaling pathway. Cell. 2007;128(2):341-355. (Pubitemid 46123509)
34. Calvo F, Sahai E. Cell communication networks in cancer invasion. Curr Opin Cell Biol. 2011;23(5): 621-629.
35. Malumbres M, BarbacidM. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003;3(6):459-465. (Pubitemid 37328850)
36. Hoek KS, Eichhoff OM, Schlegel NC, et al. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res. 2008; 68(3):650-656. (Pubitemid 351206739)
37. Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med. 2006;355(1):51-65.
38. Hacker E, Hayward NK, Dumenil T, JamesMR, Whiteman DC. The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population. J Invest Dermatol. 2010;130(1):241-248.